MHRA nod for supply and use of Pfizer's COVID-19 oral antiviral

31 December 2021
mhra_large

The UK subsidiary of US pharma giant Pfizer (NYE: PFE) today announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorization for Great Britain for the supply and use of PF-07321332/ritonavir for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe disease.

Trade named Paxlovid, PF-07321332/ritonavir is a novel protease inhibitor that includes PF-07321332, a drug designed to block the activity of the 3C-like (3CL) protease, also known as the main protease (Mpro) inhibitor, that was specifically designed in Pfizer’s laboratories to combat SARS-CoV-2. 3CL protease is a virally encoded protein that is essential to enable the virus to replicate; by inhibiting this viral protein, PF-07321332 reduces the ability of the virus to reproduce.

Paxlovid is the second oral COVID-19 antiviral approved by the MHRA, which early in November cleared Merck & Co’s (NYSE: MRK) Lagevrio (molnupiravir).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical